Search Results - "JAKUPEC, M. A"

Recent Developments in the Field of Tumor-Inhibiting Metal Complexes by Galanski, M S, Arion, V B, Jakupec, M A, Keppler, B K

“…25 years after the first approval of cisplatin in the clinic against a number of cancer diseases, cisplatin and related compounds continue to be among the most…”
Get more information

Multi-scale imaging of anticancer platinum() compounds in murine tumor and kidney by Legin, A. A, Theiner, S, Schintlmeister, A, Reipert, S, Heffeter, P, Jakupec, M. A, Mayr, J, Varbanov, H. P, Kowol, C. R, Galanski, M. S, Berger, W, Wagner, M, Keppler, B. K

“…Nano-scale secondary ion mass spectrometry (NanoSIMS) enables trace element and isotope analyses with high spatial resolution. This unique capability has…”
Get full text

Improved reaction conditions for the synthesis of new NKP-1339 derivatives and preliminary investigations on their anticancer potential by Kuhn, P-S, Pichler, V, Roller, A, Hejl, M, Jakupec, M A, Kandioller, W, Keppler, B K

“…The very promising results of Na-trans-[RuCl4(1H-indazole)2] (NKP-1339) in clinical studies have fuelled renewed interest in the research and development of…”
Get more information

Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells by KAPITZA, S, PONGRATZ, M, JAKUPEC, M. A, HEFFETER, P, BERGER, W, LACKINGER, L, KEPPLER, B. K, MARIAN, B

“…The ruthenium complex salt indazolium trans-[tetrachlorobisindazole-ruthenate(III)] (KP1019) and the analogous sodium salt KP1339 are effective…”
Get full text

Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24) by Heffeter, P., Jakupec, M.A., Körner, W., Chiba, P., Pirker, C., Dornetshuber, R., Elbling, L., Sutterlüty, H., Micksche, M., Keppler, B.K., Berger, W.

“…Recently, we have introduced [tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772, FFC24) as a new lanthanum compound which has promising anticancer…”
Get full text

Tumour-inhibiting platinum complexes--state of the art and future perspectives by Jakupec, M A, Galanski, M, Keppler, B K

“…Thirty years after the onset of the first clinical studies with cisplatin, the development of antineoplastic platinum drugs continues to be a productive field…”
Get more information

Pharmacological properties of cerium compounds by Jakupec, M A, Unfried, P, Keppler, B K

“…Cerium is a member of the lanthanide series or rare earth elements which exert diverse biological effects mainly by their resemblance to calcium. This…”
Get more information

Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A) by Heffeter, P, Pongratz, M, Steiner, E, Chiba, P, Jakupec, M A, Elbling, L, Marian, B, Körner, W, Sevelda, F, Micksche, M, Keppler, B K, Berger, W

“…KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A) is a metal complex with promising anticancer activity. Since chemoresistance is…”
Get more information

KP1019 (FFC14A) from bench to bedside: preclinical and early clinical development--an overview by Jakupec, M A, Arion, V B, Kapitza, S, Reisner, E, Eichinger, A, Pongratz, M, Marian, B, Graf von Keyserlingk, N, Keppler, B K

Get full text

Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors--a CESAR study (Central European Society for Anticancer Drug Research--EWIV) by Hofheinz, R D, Dittrich, C, Jakupec, M A, Drescher, A, Jaehde, U, Gneist, M, Graf von Keyserlingk, N, Keppler, B K, Hochhaus, A

Get full text

Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772) by Heffeter, P, Popovic-Bijelic, A, Saiko, P, Dornetshuber, R, Jungwirth, U, Voevodskaya, N, Biglino, D, Jakupec, M A, Elbling, L, Micksche, M, Szekeres, T, Keppler, B K, Gräslund, A, Berger, W

“…KP772 is a new lanthanum complex containing three 1,10-phenathroline molecules. Recently, we have demonstrated that the promising in vitro and in vivo…”
Get more information

Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion by Bergamo, A., Masi, A., Jakupec, M. A., Keppler, B. K., Sava, G.

“…The effects of indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019, or FFC14A), the second ruthenium compound that entered clinical trials, in…”
Get full text

Rational development of oxaliplatin analogues --synthesis and preliminary structure-activity relationships by Galanski, M, Habala, L, Nazarov, A A, Jakupec, M A, Yasemi, A, Slaby, S, Graf von Keyserlingk, N, Keppler, B K

Get full text

Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches by Galanski, Mathea Sophia, Jakupec, Michael A, Keppler, Bernhard K

“…Research in the field of bioinorganic chemistry has been stimulated by the worldwide success of the anticancer drug cisplatin. 40 years after the first report…”
Get more information

Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP by Schluga, Petra, Hartinger, Christian G, Egger, Alexander, Reisner, Erwin, Galanski, Markus, Jakupec, Michael A, Keppler, Bernhard K

“…Biotransformation of ruthenium(III) anticancer complexes as hypothesized in the activation-by-reduction theory is the central topic of the present paper. The…”
Get more information

Gallium(III) and Iron(III) Complexes of α-N-Heterocyclic Thiosemicarbazones:  Synthesis, Characterization, Cytotoxicity, and Interaction with Ribonucleotide Reductase by Kowol, Christian R, Berger, Roland, Eichinger, Rene, Roller, Alexander, Jakupec, Michael A, Schmidt, Peter P, Arion, Vladimir B, Keppler, Bernhard K

“…A series of gallium(III) and iron(III) complexes with five different 4N-substituted α-N-heterocyclic thiosemicarbazones, viz., 2-acetylpyridine…”
Get full text

Redox-Active Antineoplastic Ruthenium Complexes with Indazole:  Correlation of in Vitro Potency and Reduction Potential by JAKUPEC, Michael A., REISNER, Erwin, EICHINGER, Anna, PONGRATZ, Martina, ARION, Vladimir B., GALANSKI, Markus, HARTINGER, Christian G., KEPPLER, Bernhard K.

“…Antineoplastic ruthenium(III) complexes are generally regarded as prodrugs, being activated by reduction. Within a homologous series of ruthenium(III)…”
Get full text

Gallium in cancer treatment by Jakupec, Michael A, Keppler, Bernhard K

“…The trivalent gallium cation is capable of inhibiting tumor growth, mainly because of its resemblance to ferric iron. It affects cellular acquisition of iron…”
Get more information

The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells by Kapitza, Susanne, Jakupec, Michael A., Uhl, Maria, Keppler, Bernhard K., Marian, Brigitte

“…The Ru(III) complex salt KP1019 induced formation of H 2O 2 in colorectal tumor cells in a dose-dependent way. It also caused DNA-strand breaks if only weakly…”
Get full text

Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24) by Heffeter, Petra, Jakupec, Michael A., Körner, Wilfried, Wild, Stefan, von Keyserlingk, Nikolai Graf, Elbling, Leonilla, Zorbas, Haralabos, Korynevska, Alla, Knasmüller, Siegfried, Sutterlüty, Hedwig, Micksche, Michael, Keppler, Bernhard K., Berger, Walter

“…Aim of this study was to investigate the anticancer properties of the new lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772;…”
Get full text